484 related articles for article (PubMed ID: 29843107)
1. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
[TBL] [Abstract][Full Text] [Related]
2. Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors.
Kahn AM; Perry CJ; Etts K; Kluger H; Sznol M
Oncologist; 2024 Apr; 29(4):e507-e513. PubMed ID: 37971411
[TBL] [Abstract][Full Text] [Related]
3. First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.
Schilling B; Martens A; Geukes Foppen MH; Gebhardt C; Hassel JC; Rozeman EA; Gesierich A; Gutzmer R; Kähler KC; Livingstone E; Diamantopoulos PT; Gogas H; Madonna G; Ascierto PA; Goldinger SM; Mangana J; Garbe C; Schadendorf D; Blank C; Weide B
Cancer Immunol Immunother; 2019 May; 68(5):765-772. PubMed ID: 30806748
[TBL] [Abstract][Full Text] [Related]
4. Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.
Wilson MA; Zhao F; Letrero R; D'Andrea K; Rimm DL; Kirkwood JM; Kluger HM; Lee SJ; Schuchter LM; Flaherty KT; Nathanson KL
Clin Cancer Res; 2014 Jun; 20(12):3328-37. PubMed ID: 24714776
[TBL] [Abstract][Full Text] [Related]
5. Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
Shattuck-Brandt RL; Chen SC; Murray E; Johnson CA; Crandall H; O'Neal JF; Al-Rohil RN; Nebhan CA; Bharti V; Dahlman KB; Ayers GD; Yan C; Kelley MC; Kauffmann RM; Hooks M; Grau A; Johnson DB; Vilgelm AE; Richmond A
Clin Cancer Res; 2020 Jul; 26(14):3803-3818. PubMed ID: 32234759
[TBL] [Abstract][Full Text] [Related]
6. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
7. Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma.
Hassel JC; Buder-Bakhaya K; Bender C; Zimmer L; Weide B; Loquai C; Ugurel S; Slynko A; Gutzmer R;
Cancer Med; 2018 Jan; 7(1):95-104. PubMed ID: 29266761
[TBL] [Abstract][Full Text] [Related]
8. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced
Atkins MB; Lee SJ; Chmielowski B; Tarhini AA; Cohen GI; Truong TG; Moon HH; Davar D; O'Rourke M; Stephenson JJ; Curti BD; Urba WJ; Brell JM; Funchain P; Kendra KL; Ikeguchi AP; Jaslowski A; Bane CL; Taylor MA; Bajaj M; Conry RM; Ellis RJ; Logan TF; Laudi N; Sosman JA; Crockett DG; Pecora AL; Okazaki IJ; Reganti S; Chandra S; Guild S; Chen HX; Streicher HZ; Wolchok JD; Ribas A; Kirkwood JM
J Clin Oncol; 2023 Jan; 41(2):186-197. PubMed ID: 36166727
[TBL] [Abstract][Full Text] [Related]
9. Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey.
Fabre M; Lamoureux A; Meunier L; Samaran Q; Lesage C; Girard C; Du Thanh A; Moulis L; Dereure O
Melanoma Res; 2024 Jun; 34(3):241-247. PubMed ID: 38546723
[TBL] [Abstract][Full Text] [Related]
10. Melanoma: What do all the mutations mean?
Davis EJ; Johnson DB; Sosman JA; Chandra S
Cancer; 2018 Sep; 124(17):3490-3499. PubMed ID: 29663336
[TBL] [Abstract][Full Text] [Related]
11. BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms.
Dinter L; Karitzky PC; Schulz A; Wurm AA; Mehnert MC; Sergon M; Tunger A; Lesche M; Wehner R; Müller A; Käubler T; Niessner H; Dahl A; Beissert S; Schmitz M; Meier F; Seliger B; Westphal D
Int J Cancer; 2024 Mar; 154(6):1057-1072. PubMed ID: 38078628
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma.
Moya-Plana A; Herrera Gómez RG; Rossoni C; Dercle L; Ammari S; Girault I; Roy S; Scoazec JY; Vagner S; Janot F; Eggermont AMM; Robert C
Cancer Immunol Immunother; 2019 Jul; 68(7):1171-1178. PubMed ID: 31172258
[TBL] [Abstract][Full Text] [Related]
13. COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma.
van Akkooi AC; Hauschild A; Long GV; Mandala M; Kicinski M; Govaerts AS; Klauck I; Ouali M; Lorigan PC; Eggermont AM
Future Oncol; 2023 Sep; 19(30):2017-2027. PubMed ID: 37665297
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma.
Colombino M; Lissia A; Capone M; De Giorgi V; Massi D; Stanganelli I; Fonsatti E; Maio M; Botti G; Caracò C; Mozzillo N; Ascierto PA; Cossu A; Palmieri G
J Transl Med; 2013 Aug; 11():202. PubMed ID: 23987572
[TBL] [Abstract][Full Text] [Related]
15. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.
Dahlman KB; Xia J; Hutchinson K; Ng C; Hucks D; Jia P; Atefi M; Su Z; Branch S; Lyle PL; Hicks DJ; Bozon V; Glaspy JA; Rosen N; Solit DB; Netterville JL; Vnencak-Jones CL; Sosman JA; Ribas A; Zhao Z; Pao W
Cancer Discov; 2012 Sep; 2(9):791-7. PubMed ID: 22798288
[TBL] [Abstract][Full Text] [Related]
16. Targeted next-generation sequencing of Japanese patients with sinonasal mucosal melanomas identifies frequent NRAS and CTNNB1 mutations.
Tsushima N; Kano S; Hatanaka KC; Suzuki T; Hamada S; Idogawa H; Nakamaru Y; Suzuki M; Hatanaka Y; Homma A
Auris Nasus Larynx; 2024 Apr; 51(2):313-319. PubMed ID: 37953090
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses.
Friedman CF; Spencer C; Cabanski CR; Panageas KS; Wells DK; Ribas A; Tawbi H; Tsai K; Postow M; Shoushtari A; Chapman P; Karakunnel J; Bucktrout S; Gherardini P; Hollmann TJ; Chen RO; Callahan M; LaVallee T; Ibrahim R; Wolchok J
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35074903
[TBL] [Abstract][Full Text] [Related]
18. Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes.
Thomas NE; Edmiston SN; Orlow I; Kanetsky PA; Luo L; Gibbs DC; Parrish EA; Hao H; Busam KJ; Armstrong BK; Kricker A; Cust AE; Anton-Culver H; Gruber SB; Gallagher RP; Zanetti R; Rosso S; Sacchetto L; Dwyer T; Ollila DW; Begg CB; Berwick M; Conway K;
J Invest Dermatol; 2018 Nov; 138(11):2398-2404. PubMed ID: 29753029
[TBL] [Abstract][Full Text] [Related]
19. The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns.
Amini-Adle M; Arnault JP; Aubin F; Beneton N; Bens G; Brunet-Possenti F; Célerier P; Charles J; Crumbach L; Dalac S; Darras S; De Quatrebarbes J; Dinulescu M; Dutriaux C; Gaudy C; Gérard E; Giacchero D; Granel-Brocard F; Grange F; Jouary T; Kramkimel N; Lebbé C; Le Corre Y; Legoupil D; Lesage C; Lesimple T; Lorphelin JM; Mansard S; Martin L; Mary-Prey S; Maubec E; Meyer N; Mignard C; Montaudie H; Mortier L; Nardin C; Neidhardt Berard EM; Pagès Laurent C; Peuvrel L; Quereux G; Robert C; Saiag P; Saint-Jean M; Samimi M; Sassolas B; Scalbert C; Skowron F; Steff M; Stoebner PE; Trablesi S; Visseaux L; Zehou O; Boespflug A;
Ann Dermatol Venereol; 2024 Mar; 151(1):103243. PubMed ID: 38325268
[No Abstract] [Full Text] [Related]
20. Associations of MC1R Genotype and Patient Phenotypes with BRAF and NRAS Mutations in Melanoma.
Thomas NE; Edmiston SN; Kanetsky PA; Busam KJ; Kricker A; Armstrong BK; Cust AE; Anton-Culver H; Gruber SB; Luo L; Orlow I; Reiner AS; Gallagher RP; Zanetti R; Rosso S; Sacchetto L; Dwyer T; Parrish EA; Hao H; Gibbs DC; Frank JS; Ollila DW; Begg CB; Berwick M; Conway K;
J Invest Dermatol; 2017 Dec; 137(12):2588-2598. PubMed ID: 28842324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
